Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.45 |
| ▸ | AVPR1A | P37288 | 5/20 | 0.42 |
| ▸ | NAMPT | P43490 | 6/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30527626 | 1.00 | NR1H2 (0.45) | NR1H2AVPR1ANAMPTGPR119 | |
| SCHEMBL4065831 | 0.88 | AVPR1A (0.51) | AVPR1ANAMPTGPR119 | |
| SCHEMBL3223037 | 0.83 | AVPR1A (0.53) | NR1H2AVPR1ANAMPTGPR119 | |
| SCHEMBL30008913 | 0.83 | AVPR1A (0.53) | NR1H2AVPR1ANAMPTGPR119 | |
| SCHEMBL29871828 | 0.81 | AVPR1A (0.45) | AVPR1ANAMPT | |
| SCHEMBL20502778 | 0.80 | RORC (0.41) | NR1H2AVPR1A | |
| SCHEMBL15507949 | 0.79 | NR1H2 (0.43) | NR1H2AVPR1A | |
| SCHEMBL15508228 | 0.77 | NR1H2 (0.42) | NR1H2AVPR1AGPR119 | |
| SCHEMBL16864998 | 0.77 | AVPR1A (0.40) | NR1H2AVPR1AGPR119 | |
| SCHEMBL12097232 | 0.76 | RORC (0.40) | NR1H2AVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250215029-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. | 2025-07-03 | — | — | US | disclosed |
| EP-4463459-A1 | STAT MODULATORS AND USES THEREOF | Recludix Pharma, Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| CN-118804917-A | STAT modulators and uses thereof | 瑞克鲁迪克斯制药股份有限公司 | 2024-10-18 | — | — | CN | disclosed |
| WO-2023133336-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| WO-2023133336-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250215029-A1 | STAT MODULATORS AND USES THEREOF | STAT6, STAT3, STAT5A | NR1H2 926/4885AVPR1A 2684/4885NAMPT 1463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.